INSYS Therapeutics, Inc. announced that Clinical data from a long-term safety study of pharmaceutical-grade cannabidiol (CBD) oral solution as an investigational treatment for refractory pediatric epilepsy will be presented on Dec. 3 at the 2018 American Epilepsy Society (AES) annual meeting in New Orleans. The product candidate evaluated in the study is from INSYS Therapeutics, Inc. The AES poster presentation on this multicenter, open-label, flexible-dose study (INS011-14-030) is titled Long-Term Safety of Pharmaceutical Cannabidiol Oral Solution as Adjunctive Treatment for Pediatric Patients with Treatment-Resistant Epilepsy. Other clinical research on CBD from INSYS includes three ongoing company-sponsored trials: childhood absence epilepsy (Phase 2), infantile spasms (Phase 3) and Prader-Willi syndrome (Phase 2). Results from the Phase 2 trial in childhood absence epilepsy are expected soon, pending completion of enrollment. All three trials are actively enrolling patients.